PL2683381T3 - Preparat zawierający pochodną fenyloaminopirymidyny jako substancję czynną - Google Patents

Preparat zawierający pochodną fenyloaminopirymidyny jako substancję czynną

Info

Publication number
PL2683381T3
PL2683381T3 PL11764851T PL11764851T PL2683381T3 PL 2683381 T3 PL2683381 T3 PL 2683381T3 PL 11764851 T PL11764851 T PL 11764851T PL 11764851 T PL11764851 T PL 11764851T PL 2683381 T3 PL2683381 T3 PL 2683381T3
Authority
PL
Poland
Prior art keywords
formulation
active agent
phenylaminopyrimidine derivative
phenylaminopyrimidine
derivative
Prior art date
Application number
PL11764851T
Other languages
English (en)
Inventor
Durga Maheswari Parvataneni
Siddhartha Yedluri
Venkata Satyanarayana Appadwedula
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2683381(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of PL2683381T3 publication Critical patent/PL2683381T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL11764851T 2011-03-07 2011-08-10 Preparat zawierający pochodną fenyloaminopirymidyny jako substancję czynną PL2683381T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
EP11764851.9A EP2683381B1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (1)

Publication Number Publication Date
PL2683381T3 true PL2683381T3 (pl) 2016-06-30

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11764851T PL2683381T3 (pl) 2011-03-07 2011-08-10 Preparat zawierający pochodną fenyloaminopirymidyny jako substancję czynną

Country Status (32)

Country Link
US (1) US9895367B2 (pl)
EP (1) EP2683381B1 (pl)
JP (1) JP5788534B2 (pl)
KR (1) KR101767296B1 (pl)
CN (1) CN103561742B (pl)
AP (1) AP4076A (pl)
AU (1) AU2011361921B2 (pl)
BR (1) BR112013022930A2 (pl)
CA (1) CA2829015C (pl)
CO (1) CO6811851A2 (pl)
CY (1) CY1116968T1 (pl)
DK (1) DK2683381T3 (pl)
EA (1) EA024610B1 (pl)
ES (1) ES2554927T3 (pl)
GB (1) GB2488788B (pl)
GE (1) GEP20156410B (pl)
HR (1) HRP20151382T1 (pl)
HU (1) HUE025562T2 (pl)
IL (1) IL228218A (pl)
MA (1) MA35088B1 (pl)
MX (1) MX339130B (pl)
MY (1) MY158693A (pl)
NZ (1) NZ614903A (pl)
PL (1) PL2683381T3 (pl)
PT (1) PT2683381E (pl)
RS (1) RS54420B1 (pl)
SG (1) SG193349A1 (pl)
SI (1) SI2683381T1 (pl)
SM (1) SMT201500235B (pl)
UA (1) UA111074C2 (pl)
WO (1) WO2012120328A1 (pl)
ZA (1) ZA201306643B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3389633T3 (pl) * 2015-12-18 2021-12-13 Natco Pharma Ltd Kompozycje farmaceutyczne zawierające pochodną fenyloaminopirymidyny
WO2017115316A1 (en) * 2015-12-29 2017-07-06 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
UA128159C2 (uk) * 2018-03-14 2024-04-24 Канді Терап'Ютікс Лімітед Фармацевтичний препарат для капсули з м'якого желатину, який містить подвійний антагоніст рецептора nk-1/nk-3
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
DE69823663T2 (de) * 1997-07-29 2005-05-19 Pharmacia & Upjohn Co., Kalamazoo Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
KR20090061068A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 이매티닙의 제조 방법
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
AU2008245404B2 (en) * 2007-04-30 2013-12-05 Intezyne Technologies, Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
US8067422B2 (en) * 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
NZ587518A (en) 2008-03-04 2012-09-28 Natco Pharma Ltd Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide
US20110160249A1 (en) * 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor

Also Published As

Publication number Publication date
CA2829015C (en) 2018-01-02
HUE025562T2 (en) 2016-03-29
BR112013022930A2 (pt) 2016-12-06
GB2488788A (en) 2012-09-12
US9895367B2 (en) 2018-02-20
CN103561742A (zh) 2014-02-05
DK2683381T3 (en) 2015-12-21
IL228218A (en) 2016-06-30
ZA201306643B (en) 2014-11-26
NZ614903A (en) 2014-08-29
CA2829015A1 (en) 2012-09-13
MA35088B1 (fr) 2014-05-02
SG193349A1 (en) 2013-10-30
GB2488788B (en) 2013-07-10
PT2683381E (pt) 2015-11-02
JP5788534B2 (ja) 2015-09-30
CN103561742B (zh) 2016-04-27
JP2014507463A (ja) 2014-03-27
AP4076A (en) 2017-03-23
WO2012120328A1 (en) 2012-09-13
MX2013010160A (es) 2013-12-06
AU2011361921B2 (en) 2016-06-09
CO6811851A2 (es) 2013-12-16
UA111074C2 (uk) 2016-03-25
SMT201500235B (it) 2015-10-30
US20130338180A1 (en) 2013-12-19
ES2554927T3 (es) 2015-12-28
RS54420B1 (en) 2016-04-28
MY158693A (en) 2016-11-15
CY1116968T1 (el) 2017-04-05
EP2683381B1 (en) 2015-09-16
KR20140016926A (ko) 2014-02-10
AU2011361921A2 (en) 2014-10-30
GB201103860D0 (en) 2011-04-20
AU2011361921A1 (en) 2013-09-26
AP2013007128A0 (en) 2013-09-30
KR101767296B1 (ko) 2017-08-10
HRP20151382T1 (hr) 2016-02-12
EP2683381A1 (en) 2014-01-15
GEP20156410B (en) 2015-12-10
EA024610B1 (ru) 2016-10-31
EA201391280A1 (ru) 2014-02-28
SI2683381T1 (sl) 2016-01-29
MX339130B (es) 2016-05-13

Similar Documents

Publication Publication Date Title
HK1192152A1 (zh) 新型抗紅班活性劑和含相同的組合物
GB201111438D0 (en) Formulation
ZA201309221B (en) Formulation
EP2787071A4 (en) EPIC-CONTAINING CONCENTRATION AGENT CONTAINING PSICOSIS AS AN ACTIVE INGREDIENT
SMT201500235B (it) Formulazione comprendente derivato di fenilamminopirimidina come agente attivo
PT2739276T (pt) Composição antisséptica
HK1203480A1 (en) Ophthalmic formulation
GB2525835B (en) Pharmaceutical agent
PL2701506T3 (pl) Składnik formulacji
ZA201402456B (en) Formulation
ZA201305986B (en) Improved insecticide formulations
GB201121377D0 (en) Formulation component
GB201107039D0 (en) Formulation component
HK1187821A1 (en) A topical formulation comprising a corticosteroid as active ingredient
HUE037814T2 (hu) Formulációs összetevõ
GB201106958D0 (en) Formulation
GB201104284D0 (en) Formulation
AU2011902822A0 (en) Disinfecting formulation
GB201110027D0 (en) Topical formulation
GB201110030D0 (en) Topical formulation
AU2011905445A0 (en) Formulation
AU2011905442A0 (en) Formulation
AU2011904841A0 (en) Formulation
ZA201201024B (en) Pesticidal formulation
GB201108234D0 (en) Pharmaceutical agent